A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience

• Published in: Journal of headache and pain Vol. 17; no. 1; p. 1
• Main Authors: Negro, Andrea, Curto, Martina, Lionetto, Luana, Martelletti, Paolo
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 21.01.2016; Springer Nature B.V
• Subjects: Acetylcholine Release Inhibitors - therapeutic use; Adolescent; Adult; Aged; Botulinum Toxins, Type A - therapeutic use; Chronic illnesses; Clinical outcomes; Drug use; Female; Headache Disorders, Secondary - drug therapy; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Migraine; Migraine Disorders - drug therapy; Neurology; Pain Medicine; Prescription Drug Overuse; Prescription drugs; Prospective Studies; Research Article; Treatment Outcome; Young Adult; Chronic migraine; OnabotulinumtoxinA; Migraine abuse; Medication overuse headache; Preventative therapy

Background The efficacy and safety of OnabotulinumtoxinA (BOTOX®) in adults with chronic migraine (CM) were demonstrated in the PREEMPT program. However, the dosage used in this study was flexible from 155 U to 195 U at the physician’s discretion. Therefore, the objective of this prospective study w...